42
Participants
Start Date
July 17, 2011
Primary Completion Date
April 3, 2017
Study Completion Date
April 3, 2017
Cyclophosphamide
150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
Fludarabine
12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
Rituximab
375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
Haemek Medical Center; Hematology Department, Afula
Western Galilee Hospital - Nahariya, Nahariya
Meir Medical Center; Internal Dept A, Kfar Saba
Beilinson Medical Center; Haematology, Petah Tikva
ASSAF Harofe; Department of Hematology, Rishon LeZiyyon
Rambam Medical Center; Heamatology & Bone Marrow Transplantation, Haifa
Bnei-Zion Medical Center; Hematology Dept, Haifa
Ichilov Sourasky Medical Center; Heamatology, Tel Aviv
Kaplan Medical Center, Rehovot
Soroka Medical Center; Hematology Deptartment, Beersheba
Shaare Zedek Medical Center; Hematology Dept., Jerusalem
Hadassah Ein Karem Hospital; Haematology, Jerusalem
Hoffmann-La Roche
INDUSTRY